{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T10:52:49Z","timestamp":1783075969589,"version":"3.54.6"},"reference-count":28,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2010,8,1]],"date-time":"2010-08-01T00:00:00Z","timestamp":1280620800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"crossref","award":["303106"],"award-info":[{"award-number":["303106"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Biological Psychiatry"],"published-print":{"date-parts":[[2010,8]]},"DOI":"10.1016\/j.biopsych.2010.04.003","type":"journal-article","created":{"date-parts":[[2010,5,27]],"date-time":"2010-05-27T13:03:12Z","timestamp":1274965392000},"page":"296-302","source":"Crossref","is-referenced-by-count":31,"title":["Risk Factors for Craving and Relapse in Heroin Users Treated with Oral or Implant Naltrexone"],"prefix":"10.1016","volume":"68","author":[{"given":"Gary K.","family":"Hulse","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanh T.T.","family":"Ngo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert J.","family":"Tait","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.biopsych.2010.04.003_bib1","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1080\/13556210220139541","article-title":"Serum naltrexone and 6-beta-naltrexol levels from naltrexone implants can block very large amounts of heroin: A report of two cases","volume":"7","author":"Brewer","year":"2002","journal-title":"Addict Biol"},{"key":"10.1016\/j.biopsych.2010.04.003_bib2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0376-8716(85)90076-6","article-title":"Clinical evaluation of a naltrexone sustained-release preparation","volume":"16","author":"Chiang","year":"1985","journal-title":"Drug Alcohol Depend"},{"key":"10.1016\/j.biopsych.2010.04.003_bib3","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/0376-8716(94)90161-9","article-title":"Determination of naltrexone dosage for narcotic agonist blockade in detoxified Asian addicts","volume":"34","author":"Navaratnam","year":"1994","journal-title":"Drug Alcohol Depend"},{"key":"10.1016\/j.biopsych.2010.04.003_bib4","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1002\/cpt1976203315","article-title":"Naltrexone: Disposition, metabolism, and effects after acute and chronic dosing","volume":"20","author":"Verebey","year":"1976","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.biopsych.2010.04.003_bib5","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD001333","article-title":"Naltrexone maintenance treatment for opioid dependence","volume":"2","author":"Kirchmayer","year":"2003","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.biopsych.2010.04.003_bib6","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1517\/13543784.16.8.1285","article-title":"Sustained-release naltrexone: Novel treatment for opioid dependence","volume":"16","author":"Comer","year":"2007","journal-title":"Expert Opin Investig Drugs"},{"key":"10.1016\/j.biopsych.2010.04.003_bib7","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1001\/archpsyc.63.2.210","article-title":"Injectable, sustained-release naltrexone for the treatment of opioid dependence: A randomized, placebo-controlled trial","volume":"63","author":"Comer","year":"2006","journal-title":"Arch Gen Psychiatry"},{"key":"10.1016\/j.biopsych.2010.04.003_bib8","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1192\/bjp.bp.108.055319","article-title":"Naltrexone implants after in-patient treatment for opioid dependence: Randomised controlled trial","volume":"194","author":"Kunoe","year":"2009","journal-title":"Br J Psychiatry"},{"key":"10.1016\/j.biopsych.2010.04.003_bib9","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1001\/archgenpsychiatry.2009.130","article-title":"Improving clinical outcomes in treating heroin dependence","volume":"66","author":"Hulse","year":"2009","journal-title":"Arch Gen Psychiatry"},{"key":"10.1016\/j.biopsych.2010.04.003_bib10","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1080\/13556210410001674103","article-title":"Blood naltrexone and 6-\u03b2-naltrexol levels following naltrexone implant: Comparing two naltrexone implants","volume":"9","author":"Hulse","year":"2004","journal-title":"Addict Biol"},{"key":"10.1016\/j.biopsych.2010.04.003_bib11","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.pnpbp.2007.06.007","article-title":"Blood naltrexone levels over time following naltrexone implants","volume":"32","author":"Ngo","year":"2008","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"10.1016\/j.biopsych.2010.04.003_bib12","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1080\/09595230096138","article-title":"The association between naltrexone compliance and daily supervision","volume":"19","author":"Hulse","year":"2000","journal-title":"Drug Alcohol Rev"},{"key":"10.1016\/j.biopsych.2010.04.003_bib13","series-title":"The Opiate Treatment Index (OTI) Researchers' Manual","author":"Darke","year":"1991"},{"key":"10.1016\/j.biopsych.2010.04.003_bib14","series-title":"Free Naltrexone and 6-\u03b2-Naltrexol in Whole Blood by LC-MS-MS","author":"Hansson","year":"2000"},{"key":"10.1016\/j.biopsych.2010.04.003_bib15","series-title":"SAS","year":"2002"},{"key":"10.1016\/j.biopsych.2010.04.003_bib16","series-title":"How to Use SAS for Logistic Regression with Correlated Data","year":"2002"},{"key":"10.1016\/j.biopsych.2010.04.003_bib17","first-page":"672","article-title":"Implantable narcotic antagonists: A possible new treatment for narcotic addiction","volume":"21","author":"Chiang","year":"1985","journal-title":"Psychopharmacol Bull"},{"key":"10.1016\/j.biopsych.2010.04.003_bib18","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/j.drugalcdep.2005.02.009","article-title":"Reducing hospital presentations for opioid overdose in patients treated with sustained release naltrexone implants","volume":"79","author":"Hulse","year":"2005","journal-title":"Drug Alcohol Depend"},{"key":"10.1016\/j.biopsych.2010.04.003_bib19","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1111\/j.1369-1600.2007.00067.x","article-title":"Does naltrexone affect craving in abstinent opioid-dependent patients?","volume":"12","author":"Dijkstra","year":"2007","journal-title":"Addict Biol"},{"key":"10.1016\/j.biopsych.2010.04.003_bib20","doi-asserted-by":"crossref","first-page":"415","DOI":"10.3109\/00952997809007017","article-title":"Craving in heroin addicts maintained on the opiate antagonist naltrexone","volume":"5","author":"Sideroff","year":"1978","journal-title":"Am J Drug Alcohol Abuse"},{"key":"10.1016\/j.biopsych.2010.04.003_bib21","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/j.jsat.2004.02.002","article-title":"Naltrexone for heroin dependence treatment in St. Petersburg, Russia","volume":"26","author":"Krupitsky","year":"2004","journal-title":"J Subst Abuse Treat"},{"key":"10.1016\/j.biopsych.2010.04.003_bib22","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/j.jsat.2006.05.005","article-title":"Naltrexone with or without fluoxetine for preventing relapse to heroin addiction in St. Petersburg, Russia","volume":"31","author":"Krupitsky","year":"2006","journal-title":"J Subst Abuse Treat"},{"key":"10.1016\/j.biopsych.2010.04.003_bib23","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.biopsycho.2005.06.005","article-title":"A new approach to preventing relapse in opiate addicts: A psychometric evaluation","volume":"71","author":"Gr\u00fcsser","year":"2006","journal-title":"Biol Psychol"},{"key":"10.1016\/j.biopsych.2010.04.003_bib24","first-page":"15","article-title":"Bioequivalence, dose-proportionality, and pharmacokinetics of naltrexone after oral administration","volume":"45","author":"Meyer","year":"1984","journal-title":"J Clin Psychiatry"},{"key":"10.1016\/j.biopsych.2010.04.003_bib25","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.drugalcdep.2006.03.007","article-title":"Behavioral economic analysis of opioid consumption in heroin-dependent individuals: Effects of unit price and pre-session drug supply","volume":"85","author":"Greenwald","year":"2006","journal-title":"Drug Alcohol Depend"},{"key":"10.1016\/j.biopsych.2010.04.003_bib26","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/j.jsat.2006.05.009","article-title":"Heroin and cocaine craving and use during treatment: Measurement validation and potential relationships","volume":"31","author":"Heinz","year":"2006","journal-title":"J Subst Abuse Treat"},{"key":"10.1016\/j.biopsych.2010.04.003_bib27","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1016\/S0306-4603(01)00201-5","article-title":"Initial validation of two opiate craving questionnaires: The Obsessive Compulsive Drug Use Scale and the Desires for Drug Questionnaire","volume":"27","author":"Franken","year":"2002","journal-title":"Addict Behav"},{"key":"10.1016\/j.biopsych.2010.04.003_bib28","series-title":"J Psychopharmacol","article-title":"Hospital psychiatric comorbidity and its role in heroin dependence treatment outcomes using naltrexone implant or methadone maintenance","author":"Ngo","year":"2010"}],"container-title":["Biological Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S000632231000346X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S000632231000346X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,12,10]],"date-time":"2018-12-10T21:55:20Z","timestamp":1544478920000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S000632231000346X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,8]]},"references-count":28,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2010,8]]}},"alternative-id":["S000632231000346X"],"URL":"https:\/\/doi.org\/10.1016\/j.biopsych.2010.04.003","relation":{},"ISSN":["0006-3223"],"issn-type":[{"value":"0006-3223","type":"print"}],"subject":[],"published":{"date-parts":[[2010,8]]}}}